Загрузка...
Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy
ROS1 gene‐rearrangement in non‐small‐cell lung cancer (NSCLC) patients has recently been identified as a driver gene and benefited from crizotinib treatment. However, no data are available for ROS1‐positive NSCLC about chemotherapeutic options and prognostic data. We investigated pemetrexed‐based tr...
Сохранить в:
| Опубликовано в: : | Cancer Med |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5083720/ https://ncbi.nlm.nih.gov/pubmed/27544536 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.809 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|